Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. - Test2 - elhamkhani - TriplyDB

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

http://www.wikidata.org/entity/Q33623078

about

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Ceftolozane/Tazobactam.Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.

P2860

Q26747429-F4BA4269-1CA5-41AB-82FD-812A1E9E9827 Q28069563-EF72F323-889D-4AE7-8540-B6DA87B6370D Q33630591-B1B0C487-615B-4FD3-AE1E-37ECCD07FA44 Q34688710-1DBFCB06-71C6-4C70-9BA3-9088674FDC1F Q35004269-228B5731-EC07-41E7-B873-0C8C72D902B2 Q36055019-E75E5241-C325-4FBB-90F1-FD6961AD799C Q36644705-DA7001FC-42DF-4ACC-8838-084275813437 Q36740013-EB58443A-A246-441F-ADBE-1445FA6C6F30 Q38222497-F61F56F0-DBC4-4389-BA55-AC8B1EF1AF27 Q38241417-8CC2375C-685D-48EB-8D99-9A4ADD7A6816 Q38262205-7C6DB4F9-43CB-463B-950D-3F3593FC1626 Q38296151-D73A293C-7ECE-4AFC-A779-ABDDA50F3860 Q38541624-EC47926E-DD9E-4A18-8838-105D06054526 Q38544744-58CC4670-04F4-4D2D-89B2-084644AA68FE Q38648594-8C886ABC-DA44-4931-B515-44ED470B645B Q38690748-D5A8B49E-21A0-42E2-AF35-1E34898DABA7 Q38872130-1400891B-F52C-4521-98D7-3F0124761E98 Q38934400-B62E6589-8C73-4964-95C0-EB3DDC6A6888 Q39066154-FEF1503F-4195-4DD7-A1FA-D94FDC902794 Q40595075-CEA6612E-47BE-4055-A218-2248C1816643 Q41217004-8DAFC846-B75A-4838-8CD9-2042A408CCE1 Q53139521-E924CEBB-25E7-4DF6-81AA-1B6DD464BFDC

P2860

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

http://www.wikidata.org/entity/Q33623078

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@ast

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@en

type

label

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@ast

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@en

prefLabel

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@ast

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@en

P1433

Q33623078-4921EBFD-2D47-480F-9239-860FB72E82F6

P1476

Q33623078-CC5321C1-D716-4E6B-A049-D82290DBDE30

P2093

Q33623078-0A33F005-85EB-432D-B089-E8D591F6B819

Q33623078-5D158B5C-4EFD-4804-80F1-67A0B797DC4A

Q33623078-6973A0CC-2105-41D8-8E43-6AB3C28A0336

Q33623078-E6864FD6-860A-49D3-B03D-AECCC0F96C8A

P2860

Q33623078-0F1CF57B-BD36-4283-8BD4-6619003965BC

Q33623078-136A4385-E9BB-4BF1-AF91-677F86CAB1B0

Q33623078-2B4CE028-0986-4C21-A021-BF3A61C1E69A

Q33623078-35EB0D84-7B98-402C-9720-7894DFF84BEE

Q33623078-7E9D8BBE-8B2C-4F3A-924F-88D6ADFF8DA3

Q33623078-A8D533FD-F068-4EC9-9E0B-456ED217C223

Q33623078-AC2C36E5-589F-4985-B2B5-6BAF6F56752B

Q33623078-C65A20A3-794B-4606-A26A-99F32CE0A5F6

Q33623078-C7237353-5937-4276-AF4E-9BD46F7D59CB

Q33623078-F3FBBF75-BA68-42F4-A9BF-CB7CE8579413

P304

Q33623078-DFE616FE-CE08-4927-ACFF-D15E19550D74

P31

Q33623078-36179E35-B626-4EA9-9DA5-F5E2A339BC98

P356

Q33623078-F81F725C-29B0-4DC5-B5C7-7AA26FB2A6D0

P407

Q33623078-7FDFAD4C-ECF8-4BAF-A247-8E34601A0A1C

P433

Q33623078-D1952775-7EED-4C3F-A5FB-3115EA56E7A9

P478

Q33623078-2FDFB70C-613E-478D-8083-25D5EEB501F4

P50

Q33623078-50EE5CA2-F6E0-437F-8272-70EFD1571243

P577

Q33623078-479D1232-982A-4EEE-8722-57D556D0C368

P698

Q33623078-5E82F063-B302-4433-9FE2-4040B8F6671D

P932

Q33623078-8A01FE8E-7F17-4561-8361-DCB94A1C725A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

@en

P2093

Ellie Hershberger

http://www.w3.org/2001/XMLSchema#string

Gopal Krishna

http://www.w3.org/2001/XMLSchema#string

Gurudatt Chandorkar

http://www.w3.org/2001/XMLSchema#string

Myra Wooley

http://www.w3.org/2001/XMLSchema#string

P2860

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

New AUC-based method to estimate drug fraction removed by hemodialysis.

P304

2249-2255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02151-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin L. Miller

P577

2014-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24492369

http://www.w3.org/2001/XMLSchema#string

P932

4023800

http://www.w3.org/2001/XMLSchema#string